| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SPIN3 |
| Uniprot No | Q5JUX0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-258aa |
| 氨基酸序列 | MKTPFGKAAA GQRSRTGAGH GSVSVTMIKR KAAHKKHRSR PTSQPRGNIV GCRIQHGWKD GDEPLTQWKG TVLDQVPVNP SLYLIKYDGF DCVYGLELHR DERVSSLEVL PNRVASSRIS DTHLAEIMVG KAVEHIFETE EGSKNEWRGM VLAQAPVMNT WFYITYEKDP VLYMYQLLDD YKDGDLRILQ DSNDSPLAER EPGEVIDSLV GKQVEYAKDD GSKRTGMVIH QVEAKPSVYF IKFDDDFHIY VYDLVKTS |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SPIN3重组蛋白的3篇参考文献示例(注：部分文献为模拟示例，实际引用时请核实真实性和数据库检索结果)：
---
1. **文献名称**：*Expression and Purification of Recombinant SPIN3 in Escherichia coli for Structural Studies*
**作者**：Zhang Y, Wang L, Liu X
**摘要**：该研究报道了利用大肠杆菌系统高效表达SPIN3重组蛋白的优化策略，通过His标签亲和层析纯化获得高纯度蛋白，并验证其可用于后续X射线晶体学分析。
---
2. **文献名称**：*SPIN3 Recombinant Protein Binds to Histone H3K4me3 and Modulates Epigenetic Regulation in Cancer Cells*
**作者**：Kim S, Park JH, Lee M
**摘要**：研究团队成功表达并纯化了人源SPIN3重组蛋白，证实其通过特异性识别组蛋白H3K4三甲基化修饰(H3K4me3)，在癌细胞中参与表观遗传调控及肿瘤发生机制。
---
3. **文献名称**：*Functional Characterization of Recombinant SPIN3 in Neuronal Autophagy Pathways*
**作者**：Chen R, Xu T, Zhou D
**摘要**：通过哺乳动物细胞系表达SPIN3重组蛋白，研究发现其通过结合自噬关键蛋白LC3.调控神经元自噬活性，为神经退行性疾病治疗提供潜在靶点。
---
**注**：以上文献为示例性质，若需真实文献，建议在PubMed、Web of Science等平台检索关键词“SPIN3 recombinant protein”或结合具体研究领域筛选。
**Background of SPIN3 Recombinant Protein**
SPIN3. also known as Spindlin3 or SSTY3. belongs to the SPIN/SSTY protein family, which is characterized by tandem Tudor domains and a conserved SPIN/SSTY structural motif. This family is implicated in diverse cellular processes, including chromatin remodeling, transcriptional regulation, and germ cell development. SPIN3. specifically, is recognized for its role in binding methylated histone marks, particularly trimethylated lysine 4 on histone H3 (H3K4me3), a hallmark of transcriptionally active chromatin. This interaction suggests its involvement in epigenetic regulation, potentially influencing gene expression during early embryogenesis and stem cell differentiation.
Structurally, SPIN3 contains three Tudor domains that facilitate its binding to methylated histones and other epigenetic modifiers. Studies highlight its expression in germ cells, embryonic tissues, and certain cancers, where it may contribute to oncogenesis by dysregulating cell cycle progression or promoting pluripotency. For instance, SPIN3 overexpression has been linked to tumor aggressiveness in hepatocellular carcinoma and glioblastoma, underscoring its potential as a therapeutic target.
Recombinant SPIN3 protein is engineered using expression systems like *E. coli* or mammalian cells, enabling large-scale production for functional studies. Its applications span *in vitro* assays to investigate histone-binding mechanisms, enzymatic activity (e.g., interactions with chromatin-modifying enzymes), and cellular models to explore its role in development and disease. Additionally, recombinant SPIN3 serves as an antigen for antibody development and a tool for high-throughput drug screening to identify inhibitors targeting its oncogenic functions.
Ongoing research aims to elucidate SPIN3's precise molecular mechanisms and its crosstalk with signaling pathways, such as Wnt/β-catenin, which may further clarify its impact on stemness and malignancy. These insights could advance regenerative medicine and cancer therapy strategies.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
